drugset / Trial / NCT06350825
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Timeline
- Start
- 2016-01-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | — | — |
| Comparator | Apalutamide | Small molecule | — | — |
| Comparator | Darolutamide | Other / unclassified | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Enzalutamide | Other / unclassified | — | — |
| Comparator | Rezvilutamide | Unknown | — | — |